Deciphering the Potential of Bone Morphogenetic Pathway (BMP) in the Pathogenesis of Depression

Depression is a prevalent mental health disorder, profoundly impacting individuals and often exacerbated by stressful experiences. Current treatment options have limitations, including reduced efficacy and undesirable side effects. While antidepressant medications target distinct brain regions, their precise mechanisms influencing behavior remain incompletely elucidated. Recent research underscores the significance of the bone morphogenetic protein (BMP) signaling pathway within the hippocampus in mediating the effects of various antidepressants. Notably, these drugs inhibit BMP signaling, thereby augmenting neurogenesis in the hippocampus. Inhibiting BMP signaling specifically in newly generated brain cells elicits antidepressant effects, whereas suppressing these cells impedes such outcomes. This underscores the pivotal role of BMP signaling in the mechanism of antidepressant action. Adult neurogenesis, particularly in the hippocampus, emerges as pivotal for emotional regulation and stress response. Stress reduces the generation of new brain cells, whereas prolonged use of antidepressants promotes neurogenesis, suggesting a link between neurogenesis and depression. Investigating the molecular and cellular mechanisms underlying depression, anxiety, and antidepressant efficacy holds promise for the development of improved treatments characterized by rapid relief and reduced side effects.